sacituzumab
gilead
['mbc', 'bcsm', 'breast', 'trodelvy']
trodelvy continues to show durable overall survival advantage in pre-treated hr+/her2- metastatic breast cancer. #mbc #asco23 #bio23 #bcsm #bio2023 #metastatic #breastcancer #clinicaltrials #cancerresearch #denovombc 